Atai Life Sciences Announced An Update On Beckley Psytech's Phase 1/2A Trial Of ELE-101 For Major Depressive Disorder, With Initial Results From Phase 1 And The Dosing Of The First Patients In The Phase 2A Part Of The Study
Portfolio Pulse from Benzinga Newsdesk
Atai Life Sciences announced an update on Beckley Psytech's Phase 1/2A trial of ELE-101 for Major Depressive Disorder. Initial Phase 1 results were positive, and the first patients have been dosed in Phase 2A. Results are expected in H2 2024.
June 20, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atai Life Sciences announced positive initial results from Phase 1 of Beckley Psytech's ELE-101 trial and the commencement of Phase 2A dosing. Results are expected in H2 2024.
The positive initial results from Phase 1 and the commencement of Phase 2A dosing are promising for Atai Life Sciences. This progress in clinical trials could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100